PSYCHLES

From psychedelic trips to treating Treatment-Resistant Depression. The possible gamechanger COMP360 Psychiatric medicine is undergoing a seismic shift as Compass pathways announce successful results from its Phase 3 trial (COMP006).

@Drug_Science
blog on the new Compass #psilocybin for #depression study drugscience.org.uk/compass-phase3

Minds Before Brains An excerpt from my new book

A new excerpt from A World Appears: Minds Before Brains - by Michael Pollan - The Microdose themicrodose.substack.com/p/minds-befo...

Network Seminar: "Hearing voices, suicidality, and AI-psychosis", 20th March, Birmingham and Online Location In person: Assembly Room, The Exchange, 3 Centenary Square, Birmingham, B1 2DR. Online: Teams meeting. Date and time 20th March 202...

📅Save the date! Our next Network seminar will be on "Hearing voices, suicidality, and AI-psychosis", March 20th 2026, Hybrid

This is a collaboration with @hearingvoicesmic.bsky.social and #ProjectEPIC

Find more info and registration here:

birminghamphenomenalnetwork.blogspot.com/2025/12/netw...

Great day with rich discussions. The talks all went so well together. #psychedelics #phenomenology #mentalhealth @uobphenomenal.bsky.social

And we're off to the races. Great lineup for today's @uobphenomenal.bsky.social seminar. Joined by speakers from Imperial, Exeter, Amsterdam, & Birmingham. #psychedelics #interdisciplinary #phenomenology #mentalhealth

Looking forward to the talks at our Psychedelics, Phenomenology, & Mental Health workshop as part of the Birmingham Network for Phenomenology & Mental Health. Sign up & schedule in the link.

Easing End-of-Life Distress: Should Psychedelic Therapy Be Part of Palliative Care in the UK? Facing a terminal diagnosis is one of life’s most difficult challenges. Beyond the physical burden of illness, patients often experience anxiety, depression, insomnia, and existential distress – a sen...

🌿 Facing the end of life can bring immense distress. Could psychedelic therapy help ease the journey?

drugscience.org.uk/easing-end-of-life-distress-psychedelic-uk

@profjoneill.bsky.social, Laura Downey, & @profmq.bsky.social for @drugscience.bsky.social

#PalliativeCare #Psychedelics #DrugScience

The Dutch Medicines Evaluation Board will host a Pipeline Meeting on 5 Nov 2025, focusing on the regulatory development of psychedelics.

Pharmaceutical companies can apply to present and discuss psychedelic development challenges with Dutch regulators.
Deadline: 29 Aug tinyurl.com/meb-pipeline...

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation - Psychedelic Alpha Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •

Pα+ Psychedelic Bulletin #207

- Lykos Rebrands to Resilient

- Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision

- AbbVie-Gilgamesh Deal Viewed as Validation

- Psilocybin Rescheduling Petition Heads to HHS

- Much, much more...

psychedelicalpha.com/news/p%ce%b1...

SYPRES (Synthesis of Psychedelic Research Studies) logo

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...

Delighted to be part of this great new network at Birmingham, and quietly working on putting together a psychedelics and lived experience workshop as part of its activities!

Drug Science, Policy and Law Screenshot of title page and abstract

Reframing Psychedelic Regulation: Tools, not Treatments

In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.

The use of anesthetics as treatment tools in surgery is a useful analogy.

Come and study an MSc in 'Psychǝdǝlics: Mind, Medicine, and Culture' at Exeter – now on-campus too. Here's a lovely new video of one of our students, Nina, speaking on her experience:

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing Plus: Oregon Psilocybin services releases its first quarterly demographic data report and Could the Czech Republic be the first EU country to approve psilocybin-assisted therapy?

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing themicrodose.substack.com/p/texas-pass...

European Drug Report 2025: Trends and Developments now published. EUDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply and key harm reduction interventions. - www.euda.europa.eu/publications...

‪👋Hi everyone! We are an interdisciplinary group of researchers from @unibirmingham.bsky.social working on the the legal, ethical, social, and other challenges relating to the therapeutic use of psychedelics (e.g. psilocybin & MDMA). #Psychedelics #PsychedelicResearch #MedicinesRegulation

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar - Psychedelic Alpha Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with what appears to be a mandate over psychedelics…

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with a psychedelics mandate.

psychedelicalpha.com/news/matt-zo...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study - Psychedelic Alpha As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP…

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs

The results should provide a welcome catalyst for the field.

psychedelicalpha.com/news/gilgame...

The WHO has issued a rapid communication on its forthcoming guideline on controlled medicines, on which PAREA participated as an external reviewer. tinyurl.com/who-gl-rc

Taking Psychedelic Spiritualities (More) Seriously The release of a long-awaited study on psychedelics and religion ought to prompt new questions, not old cliches.

Interesting (critical) take on my recent New Yorker piece on psychedelics and religion. | Substack substack.com/home/post/p-...

Delighted to have welcomed participants to Birmingham last week for our roundtable on Psychedelics & Regulatory Decision-making. V interesting & fruitful discussion with a range of perspectives. #Psychedelics #PsychedelicExperience #PsychedelicResearch #PsychedelicMedicine #MedicinesRegulation

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2) - Psychedelic Alpha From 17–19 April, the UK’s seventh biennial psychedelic conference tackled some of the field’s most urgent questions. In this second instalment, we explore the ethical dilemmas of giving psychedelics…

Dispatch from Breaking Convention 2025: Part 2

Inside:

- Ethical dilemmas of giving psychedelics to young people

- Critical role of therapist selection,

- Female biology X psychedelics

- Pros/cons of non-hallucinogenic psychoplastogens

and more...

psychedelicalpha.com/news/dispatc...

Participate in the Global Psychedelic Survey 2025 (GPS 2025), a large global study on psychedelic use.

Sponsored by Uni of Michigan, closes May 16!

Win 1 of 15 $100 Amazon gift cards.

Take part: bit.ly/GPS2025-survey

#GPS2025 #PsychedelicResearch #GlobalSurvey